Stopping resistance to PARP drugs in prostate cancer
Ovcoming PARP Inhibitor Resistance
This project looks at why some prostate cancers stop responding to PARP inhibitor drugs and aims to find ways to help men with advanced, BRCA-related prostate cancer respond better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11247068 on NIH RePORTER |
What this research studies
The research team will study how a specific protein variant called NSD3S makes prostate cancer cells resistant to PARP inhibitor drugs. They will use laboratory cancer cells and experimental models to examine how NSD3S affects DNA replication and drug response. The investigators will also study the cellular machinery that controls NSD3S levels to identify possible ways to lower its activity. Their work is intended to point toward new drug combinations or biomarkers that could help restore PARP drug sensitivity.
Who could benefit from this research
Good fit: Ideal candidates for related future trials would be men with metastatic, castration-resistant prostate cancer, especially those whose tumors have BRCA1/2 or other homologous recombination defects.
Not a fit: Patients with early-stage prostate cancer or tumors without homologous recombination defects (non-BRCA/HRD) are less likely to benefit directly from this work.
Why it matters
Potential benefit: If successful, this work could lead to therapies or tests that let more men with advanced, BRCA-related prostate cancer benefit from PARP inhibitors.
How similar studies have performed: PARP inhibitors are already effective for some BRCA-related metastatic prostate cancers, but approaches to overcome acquired resistance are relatively new with promising lab results but limited proven clinical solutions so far.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Lou, Zhenkun — Mayo Clinic Rochester
- Study coordinator: Lou, Zhenkun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.